Patents-Review.com
ClassID:

116820 ⎘

C12Y304/21006 - CPC Classification

Classification description:

Hydrolases acting on peptide bonds, i.e. peptidases (3.4); Serine endopeptidases (3.4.21) Coagulation factor Xa (3.4.21.6)

Recent Application in this class:
#1
20250302927
2025-10-02

MODIFIED FACTOR XA POLYPEPTIDES AND METHODS OF USE

 #2
20250257347
2025-08-14

COAGULATION FACTOR X ACTIVATING ENZYME AND USE THEREOF

 #3
20250222079
2025-07-10

FX ACTIVATION PROCESS AND ITS USE IN THE PREPARATION OF A FXA COMPOSITION

 #4
20250186563
2025-06-12

UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME

 #5
20250163399
2025-05-22

LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE

 #6
20250121041
2025-04-17

HEMOSTATIC COMPOSITION CONTAINING RECOMBINANT HUMAN CLOTTING FACTORS, AND METHOD OF PRODUCING

 #7
20250092380
2025-03-20

ANTIDOTES TO FACTOR XA INHIBITORS

 #8
20240390467
2024-11-28

PROHEMOSTATIC PROTEINS FOR THE TREATMENT OF BLEEDING

 #9
20240189401
2024-06-13

UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME

 #10
20240101973
2024-03-28

METHODS AND COMPOSITIONS FOR PRODUCING VITAMIN K DEPENDENT PROTEINS

 #11
20240082367
2024-03-14

ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME

 #12
20230383276
2023-11-30

PROCESS FOR MAKING RECOMBINANT ANTIDOTE TO FACTOR XA INHIBITOR

 #13
20230000957
2023-01-05

UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME

 #14
20220354792
2022-11-10

Lyophilized formulations for factor XA antidote

 #15
20220288172
2022-09-15

Prohemostatic proteins for the treatment of bleeding

 #16
20220228131
2022-07-21

METHODS AND COMPOSITIONS FOR PRODUCING VITAMIN K DEPENDENT PROTEINS

 #17
20220177856
2022-06-09

METHODS AND COMPOSITIONS FOR PRODUCING ACTIVE VITAMIN K-DEPENDENT PROTEINS

 #18
20220135959
2022-05-05

CHIMERIC CLOTTING FACTORS

 #19
20220125894
2022-04-28

METHODS FOR TREATING INTRACRANIAL HEMORRHAGE AND ASSESSING EFFICACY

 #20
20220098565
2022-03-31

PROCESS FOR MAKING RECOMBINANT ANTIDOTE TO FACTOR XA INHIBITOR

 #21
20210379163
2021-12-09

INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES

 #22
20210371842
2021-12-02

Antidotes to factor XA inhibitors

 #23
20210340515
2021-11-04

ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME

 #24
20210332333
2021-10-28

METHODS AND COMPOSITIONS FOR PRODUCING ACTIVE VITAMIN K-DEPENDENT PROTEINS

 #25
20210290738
2021-09-23

FX activation process and its use in the preparation of a FXa composition

 #26
20210284986
2021-09-16

LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE

 #27
20210130795
2021-05-06

METHODS AND COMPOSITIONS FOR PRODUCING VITAMIN K DEPENDENT PROTEINS

 #28
20210085762
2021-03-25

UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME

 #29
20210000930
2021-01-07

COMPOSITIONS AND METHODS FOR COUNTERACTING FACTOR XA INHIBITION

 #30
20210000925
2021-01-07

Clotting composition

 #31
20200299668
2020-09-24

Lyophilized formulations for factor Xa antidote

 #32
20200299667
2020-09-24

LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE

 #33
20200299666
2020-09-24

MUTATED FACTOR X POLYPEPTIDES AND USES THEREOF FOR THE TREATMENT OF HAEMOPHILIA

 #34
20200276280
2020-09-03

Antidotes for factor Xa inhibitors and methods of using the same

 #35
20200263148
2020-08-20

METHODS AND COMPOSITIONS FOR PRODUCING VITAMIN K DEPENDENT PROTEINS

 #36
20200248162
2020-08-06

Mutated factor X polypeptides and uses thereof for the treatment of haemophilia

 #37
20200224177
2020-07-16

METHODS AND COMPOSITIONS FOR PRODUCING ACTIVE VITAMIN K-DEPENDENT PROTEINS

 #38
20200138917
2020-05-07

Prohemostatic proteins for the treatment of bleeding

 #39
20200138916
2020-05-07

Prohemostatic proteins for the treatment of bleeding

 #40
20200129597
2020-04-30

MODULATION OF FACTOR Xa INHIBITOR-MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIDOTE

 #41
20200002684
2020-01-02

METHODS AND COMPOSITIONS FOR PRODUCING VITAMIN K DEPENDENT PROTEINS

 #42
20190367888
2019-12-05

METHODS AND COMPOSITIONS FOR PRODUCING ACTIVE VITAMIN K-DEPENDENT PROTEINS

 #43
20190309279
2019-10-10

Antidotes for factor Xa inhibitors and methods of using the same

 #44
20190231856
2019-08-01

COMPOSITIONS AND METHODS FOR TREATING INTRACEREBRAL HEMORRHAGE

 #45
20190231855
2019-08-01

Compositions of human prothrombin and activated factor X for improving hemostasis in the treatment of bleeding disorders

 #46
20190225957
2019-07-25

Chimeric clotting factors

 #47
20190216884
2019-07-18

Extracellular histones as biomarkers for prognosis and molecular targets for therapy

 #48
20190153402
2019-05-23

METHODS AND COMPOSITIONS FOR PRODUCING VITAMIN K DEPENDENT PROTEINS

 #49
20190127720
2019-05-02

PROCESS FOR MAKING RECOMBINANT ANTIDOTE TO FACTOR XA INHIBITOR

 #50
20190046450
2019-02-14

LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE

 #51
20180344819
2018-12-06

Compositions and methods for counteracting Factor Xa inhibition

 #52
20180334662
2018-11-22

Mutated factor X polypeptides and uses thereof for the treatment of haemophilia

 #53
20180334658
2018-11-22

METHODS AND COMPOSITIONS FOR PRODUCING ACTIVE VITAMIN K-DEPENDENT PROTEINS

 #54
20180333469
2018-11-22

INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES

 #55
20180320160
2018-11-08

LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE

 #56
20180298350
2018-10-18

METHODS AND COMPOSITIONS FOR PRODUCING VITAMIN K DEPENDENT PROTEINS

 #57
20180251745
2018-09-06

Compositions and Methods for Modulating Hemostasis

 #58
20180236049
2018-08-23

Unit dose formulation of antidotes for factor Xa inhibitors and methods of using the same

 #59
20180185459
2018-07-05

MODULATION OF FACTOR Xa INHIBITOR-MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIDOTE

 #60
20180087039
2018-03-29

Tissue factor (TF)—targeted nanotherapy

 #61
20170369861
2017-12-28

Mutated factor X polypeptides and uses thereof for the treatment of haemophilia

 #62
20170304407
2017-10-26

Clotting composition

 #63
20170290949
2017-10-12

One component fibrin glue comprising zymogens

 #64
20170266266
2017-09-21

Functions of 55 Newfound Proteins and Their Medicinal Application in the Treatment and Prevention of Disease

 #65
20170247677
2017-08-31

Compositions and methods for modulating hemostasis

 #66
20170240879
2017-08-24

PROCESS FOR MAKING RECOMBINANT ANTIDOTE TO FACTOR XA INHIBITOR

 #67
20170233711
2017-08-17

Antidotes for factor Xa inhibitors and methods of using the same

 #68
20170232079
2017-08-17

METHOD OF MANUFACTURING PROTHROMBIN COMPLEX CONCENTRATE FROM FRACTION III AND NON-PROTHROMBIN COMPLEX CONCENTRATE FROM FRACTION IV

 #69
20170157223
2017-06-08

Prohemostatic proteins for the treatment of bleeding

 #70
20170020995
2017-01-26

Serine Protease Primary Hemostatic Agent

 #71
20170014492
2017-01-19

UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME

 #72
20160375109
2016-12-29

COMPOSITIONS AND METHODS FOR TREATING INTRACEREBRAL HEMORRHAGE

 #73
20160369257
2016-12-22

Non-cytotoxic protein conjugates

 #74
20160362673
2016-12-15

Compositions and methods for modulating hemostasis

 #75
20160354449
2016-12-08

Antidotes for factor Xa inhibitors and methods of using the same

 #76
20160326568
2016-11-10

Methods for universal determination of anticoagulant activity

 #77
20160287681
2016-10-06

Method of manufacturing and purifying prothrombin complex concentrate from Fraction III for intravenous injection and a method of curing and preventing Hemophilia A with inhibitors or Hemophilia B in patients infected with HIV-1 and HIV-2

 #78
20160237420
2016-08-18

LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE

 #79
20160187338
2016-06-30

Methods and compositions for detecting coagulation inhibitors

 #80
20160177286
2016-06-23

GLA-DOMAINLESS FACTOR X

 #81
20160145598
2016-05-26

Factor X mutants

 #82
20160138001
2016-05-19

Method for purifying active GLA-domain coagulation proteins

 #83
20160106818
2016-04-21

Human coagulation factor light chain protein and use of the same

 #84
20160046957
2016-02-18

Production of fully processed and functional factor X in a furin-secreting mammalian expression system

 #85
20160046922
2016-02-18

Factor X activation

 #86
20160015793
2016-01-21

MODULATION OF FACTOR XA INHIBITOR MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIDOTE

 #87
20160002617
2016-01-07

Antidotes for factor XA inhibitors and methods of using the same

 #88
20150376592
2015-12-31

PROCESS FOR MAKING RECOMBINANT ANTIDOTE TO FACTOR XA INHIBITOR

 #89
20150353911
2015-12-10

Chimeric clotting factors

 #90
20150352194
2015-12-10

INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES

 #91
20150344556
2015-12-03

Extracellular histones as biomarkers for prognosis and molecular targets for therapy

 #92
20150343034
2015-12-03

COMPOSITIONS AND METHODS FOR COUNTERACTING FACTOR XA INHIBITION

 #93
20150343033
2015-12-03

Use of antidotes to coagulation inhibitors indicated in the prevention or treatment of thromboembolic pathologies

 #94
20150337285
2015-11-26

Compounds and methods for purification of serine proteases

 #95
20150174215
2015-06-25

One component fibrin glue comprising zymogens

 #96
20150087066
2015-03-26

Methods and compositions for producing active vitamin K-dependent proteins

 #97
20150057228
2015-02-26

Antidotes for factor Xa inhibitors and methods of using the same

 #98
20150025011
2015-01-22

UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME

 #99
20150010997
2015-01-08

Methods and compositions for producing vitamin K dependent proteins

 #100
20140369992
2014-12-18

C-terminally tethered amino acids and their fibrinolytic therapeutic uses

 #101
20140308289
2014-10-16

Extracellular histones as biomarkers for prognosis and molecular targets for therapy

 #102
20140248259
2014-09-04

Compositions and methods for modulating hemostasis

 #103
20140120155
2014-05-01

Compositions and methods for modulating hemostasis

 #104
20140079684
2014-03-20

Antidotes for factor Xa inhibitors and methods of using the same

 #105
20140050716
2014-02-20

Procoagulant molecular decoy for treating hemophilia A or B with or without inhibitor

 #106
20140044773
2014-02-13

Antidotes for factor XA inhibitors and methods of using the same

 #107
20130129693
2013-05-23

Antidotes for factor Xa inhibitors and methods of using the same

 #108
20120321607
2012-12-20

Factor VII Fusion Polypeptides

 #109
20120309035
2012-12-06

STABLE SOLUTION

 #110
20120271039
2012-10-25

Method for purifying active GLA-domain coagulation proteins

 #111
20120269788
2012-10-25

Antidotes for factor Xa inhibitors and methods of using the same

 #112
20120231523
2012-09-13

Recombinant factor X with no glycosylation and method for preparing the same

 #113
20120207735
2012-08-16

Non-cytotoxic protein conjugates

 #114
20120178917
2012-07-12

RNA APTAMERS AND METHODS FOR IDENTIFYING THE SAME

 #115
20120087907
2012-04-12

PROTHROMBIC COMPLEX COMPOSITION

 #116
20120039863
2012-02-16

Recombinant factor X with no glycosylation and method for preparing the same

 #117
20110293597
2011-12-01

Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders

 #118
20110268724
2011-11-03

METHODS AND MATERIALS RELATING TO CD84-LIKE POLYPEPTIDES AND POLYNUCLEOTIDES

 #119
20110160443
2011-06-30

RNA aptamers and methods for identifying the same

 #120
20110159571
2011-06-30

ADENOVIRUS TARGETING

 #121
20110015128
2011-01-20

Unit dose formulation of antidotes for factor Xa inhibitors and methods of using the same

 #122
20100333218
2010-12-30

TRANSGENIC PROTEINS FROM MULTI-GENE SYSTEMS, METHODS, COMPOSITIONS, USES AND THE LIKE RELATING THERETO

 #123
20100285568
2010-11-11

Recombinant Factor X with no glycosylation and method for preparing the same

 #124
20100255586
2010-10-07

Methods and compositions for producing vitamin K dependent proteins

 #125
20100255000
2010-10-07

Antidotes for factor Xa inhibitors and methods of using the same

 #126
20100234291
2010-09-16

Preparation of low bleeding anticoagulant fusion protein and its use

 #127
20100233149
2010-09-16

Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same

 #128
20100113345
2010-05-06

Preparation of low bleeding anticoagulant fusion protein and its use

 #129
20090325226
2009-12-31

Methods and Compositions for Producing Active Vitamin K-Dependent Proteins

 #130
20090285793
2009-11-19

Thrombolytic enzyme and a process for its preparation

 #131
20090175931
2009-07-09

Compositions and methods for modulating hemostasis

 #132
20090175828
2009-07-09

Coagulation factor X polypeptides with modified activation properties

 #133
20090163429
2009-06-25

RNA aptamers and methods for identifying the same

 #134
20090117099
2009-05-07

Extracellular histones as biomarkers for prognosis and molecular targets for therapy

 #135
20090098119
2009-04-16

Antidotes for factor Xa inhibitors and methods of using the same

 #136
20090053185
2009-02-26

Coagulation factor X polypeptides with modified activation properties

 #137
20090053136
2009-02-26

Methods of Therapy and Diagnosis Using Immunotargeting of CD84Hy1-expressing Cells

 #138
20090042199
2009-02-12

Methods and Materials Relating to CD84-like Polypeptides and Polynucleotides

 #139
20090023659
2009-01-22

Methods and compositions concerning antibodies that bind CD84-like polypeptides

 #140
20080260747
2008-10-23

Methods and Materials Relating to CD84-like Polypeptides and Polynucleotides

 #141
20080241882
2008-10-02

Methods and materials relating to novel stem cell growth factor-like polypeptides and polynucleotides

 #142
20080241207
2008-10-02

Methods and materials relating to novel stem cell growth factor-like polypeptides and polynucleotides

 #143
20080221053
2008-09-11

RNA aptamers and methods for identifying the same

 #144
20080207546
2008-08-28

RNA aptamers and methods for identifying the same

 #145
20080200413
2008-08-21

RNA aptamers and methods for identifying the same

 #146
20080182809
2008-07-31

RNA aptamers and methods for identifying the same

 #147
20080009443
2008-01-10

DIAFILTRATION SYSTEM TO FRACTIONATE PROTEIN MIXTURES

 #148
20070269866
2007-11-22

Methods and compositions for producing vitamin K dependent proteins

 #149
20070231315
2007-10-04

Stabilized preparations of serine endopeptidases, their preparation and use

 #150
20060148038
2006-07-06

Thrombin cleavable factor X analogues

 #151
20060104977
2006-05-18

Methods of therapy and diagnosis using immunotargeting of CD84Hy1-expressing cells

 #152
20060052591
2006-03-09

Methods and materials relating to carcinoembryonic antigen-like (cea-like) polypeptides and polynucleotides

 #153
20050266423
2005-12-01

Novel nucleic acids and polypeptides

 #154
20050260704
2005-11-24

Thrombolytic enzyme and a process for its preparation

 #155
20050170374
2005-08-04

Novel nucleic acids and polypeptides

 #156
20050164202
2005-07-28

Materials and methods relating to therapy and diagnosis using targeting of cells that express JPL polypeptides

 #157
20050153334
2005-07-14

Methods and materials relating to novel growth regulatory-like polypeptides and polynucleotides

 #158
20050059805
2005-03-17

Method for purifying calcium ion-binding protein

 #159
20050059073
2005-03-17

Stem cell growth factor-like polypeptides

 #160
20050027114
2005-02-03

Methods and materials relating to CD84-like polypeptides and polynucleotides